PhaseBio is exploring the potential benefit of our investigational therapies in clinical trials in order to confirm their mechanisms of action in humans, to investigate their side effects and to understand the characteristics of those patients most likely to benefit.
Our lead product candidate, PB2452, is a novel ticagrelor reversal agent and we are currently conducting a Phase 2b trial in older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin.
PB1046, our long-acting VIP analogue, is currently being evaluated in a Phase 2b trial in PAH patients. Learn more about this PB1046 clinical trial in this phaware® podcast with Dr. Raymond Benza:
PhaseBio strives to work closely with patients and the scientific and regulatory communities to rapidly advance our pipeline and identify new therapeutic applications that may benefit from our ELP biopolymer technology.